Pomalidomide-C2-NH2 is primarily utilized in the development of targeted cancer therapies, particularly for the treatment of multiple myeloma. It functions as a derivative of pomalidomide, designed to enhance its binding affinity and efficacy in modulating the immune system and inducing apoptosis in cancer cells. This compound is often employed in research to create antibody-drug conjugates (ADCs), where it is linked to monoclonal antibodies to deliver cytotoxic effects directly to tumor cells while minimizing damage to healthy tissues. Additionally, it is explored in the synthesis of proteolysis-targeting chimeras (PROTACs), which degrade specific proteins involved in cancer progression. Its application extends to preclinical studies aimed at improving the pharmacokinetic properties and therapeutic outcomes of immunomodulatory drugs.